Allo HSCT Using RIC and PTCy for Hematological Diseases
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Biphenotypic Acute Leukemia|Undifferentiated Leukemia|Prolymphocytic Leukemia|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelodysplastic Syndromes|Leukemia, Myeloid|Myelodysplastic Syndrome With Excess Blasts-1|Burkitt Lymphoma|Relapsed T-Cell Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Follicular Lymphoma|Myeloproliferative Neoplasm|Myelofibrosis
BIOLOGICAL: Peripheral Blood Stem Cell Transplant|DRUG: Allopurinol 300 MG|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Bone Marrow Cell Transplant|RADIATION: Total Body Irradiation|DRUG: Sirolimus Pill|DRUG: Mycophenolate Mofetil
Evaluate rates of acute graft-versus-host disease (GVHD), Number of participants with GVHD grades 2-4 after one year post transplant., 12 months|Evaluate rates of chronic graft-versus-host disease (GVHD), Number of participants with chronic GVHD after one year post transplant., 12 months
Observe rates of relapse (RR), Number of participants that experienced relapse within 100 days of treatment., 100 days|Overall Survival (OS), Observe overall participant survival at Day 100 and at 1 and 3 years, 72 months|Observe transplant related mortality (TRM), Number of participants with transplant related mortality within 12 months of treatment., 12 months
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.